Claims of COVID-19 Cure May Cause More Neglecting Health Protocols: Expert
Translator
Editor
18 August 2020 16:08 WIB
TEMPO.CO, Jakarta - An epidemiologist Tri Yunis Miko Wahyono cast doubts on the claim of drug combinations to cure COVID-19 developed by the University of Airlangga (Unair), Surabaya.
“The results of the clinical trial still need to be questioned. What the results of the chemical and biological trials of the drug,” said Tri, who also heads the Epidemiology Department at the University of Indonesia (UI) on Tuesday, August 18.
Unair claimed to have found the antidote for the new coronavirus disease. They were the combination of Lopinavir/Ritonavir and Azithromycin, Lopinavir/Ritonavir and Doxycycline, and Hydroxychloroquine and Azithromycin.
According to Tri, the drugs were the formulation to cure Aids. Besides, the drug combinations were tested on cadets at the Army's Officer Candidate School (Secapa) who contracted the disease and that most of them were asymptomatic carriers.
This means, Tri underlined, the positive cadets had high potential to get recovered without consuming the drug combination for their strong immune system.
Tri observed that due to the lack of transparency regarding the trials of the claimed cure conducted by Unair, people could further neglect the health protocols as the antidote was already made available.
“People can think the COVID-19 cure has been found,” the epidemiologist said. “While I am sure those who are more critical will not believe it.”
Read: Epidemiologist Leery of 'COVID-19 Cure' Developed by Unair - State Intelligence
IMAM HAMDI